Synthetic hammerhead ribozymes as tools in gene expression

Critical Reviews in Oral Biology and Medicine

Volumn 12, Issue 6, 2001, Pages 469-478

  Lyngstadaas, S P ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Ribozyme applications; Ribozyme delivery; Ribozyme design; Ribozyme target selection; Synthetic hammerhead ribozymes

Indexed keywords

GENE PRODUCT; MESSENGER RNA; RIBOZYME;

CATALYSIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME STABILITY; GENE EXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA CLEAVAGE; RNA STRUCTURE;

EID: 0035674495     PISSN: 10454411     EISSN: None     Source Type: Journal    
DOI: 10.1177/10454411010120060201     Document Type: Review

References (101)

1. "Hairpin" and "hammerhead" ribozymes directed towards the mumps virus nucleocapsid RNA: Specific cleavage of a small synthetic RNA substrate and full-length mRNA
2. Hammerhead ribozyme design and application
3. Synthesis of 2′-modified nucleotides and their incorporation into hammerhead ribozymes
4. Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein Al
5. Importance of specific adenosine N3-nitrogens for efficient cleavage by a hammerhead ribozyme
6. The structure, function and application of the hammerhead ribozyme
7. Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake
8. Chemically modified hammerhead ribozymes with improved catalytic rates
9. The effect of structure in a long target RNA on ribozyme cleavage efficiency
10. Hammerhead nailed down
11. Efficient hammerhead ribozyme and antisense RNA targeting in a slow ribosome Escherichia coli mutant
12. Transient transfection of a synthetic hammerhead ribozyme targeted against human MGMT gene to cells in culture potentiates the genotoxicity of the alkylation damage induced by mitozolomide
13. Functional characterization of ribozymes expressed using U1 and T7 vectors for the intracellular cleavage of ANF mRNA
14. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormonerefractory human prostate cancer
15. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa
16. Cationic liposome-mediated transfection
17. Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint
18. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells
19. Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active site
20. Self-cleavage of virusoid RNA is performed by the proposed 55-nucleotide active site
21. Toxicity of cationic liposomeribozyme complexes in human prostate tumor cells can mimic ribozyme activity
22. Importance of specific guanosine N7-nitrogens and purine amino groups for efficient cleavage by a hammerhead ribozyme
23. Efficient hammerhead ribozymes targeted to the polycistronic Sendai virus P/C mRNA. Structure-function relationships
24. Efficient in vitro cleavage of mouse acute phase serum amyloid A mRNA mediated by a synthetic hammerhead ribozyme
25. Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2′-O-methylation
26. Ribozymes that cleave an RNA sequence from human immunodeficiency virus: The effect of flanking sequence on rate
27. Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects
28. Ribozyme-mediated inhibition of expression of leukocyte-type 12-lipoxygenase in porcine aortic vascular smooth muscle cells
29. Use of a hammerhead ribozyme with cationic liposomes to reduce leukocyte type 12-lipoxygenase expression in vascular smooth muscle
30. Simple RNA enzymes with new and highly specific endoribonuclease activities
31. Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1
32. High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine nucleosides and phosphorothioates
33. Correlation of activity with stability of chemically modified ribozymes in nuclei suspension
34. A hammerhead ribozyme cleaves its target RNA during RNA preparation
35. A comparison of the in vitro activity of DNA-armed and all-RNA hammerhead ribozymes
36. Unexpected anisotropy in substrate cleavage rates by asymmetric hammerhead ribozymes
37. Using linkers to investigate the spatial separation of the conserved nucleotides A9 and G12 in the hammerhead ribozyme
38. In vitro activity of minimised hammerhead ribozymes
39. Numbering system for the hammerhead
40. The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells
41. Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid
42. Isolation of active ribozymes from an RNA pool of random sequences using anchored substrate RNA
43. Efficient improvement of hammerhead ribozyme mediated cleavage of long substrates by oligonucleotide facilitators
44. Oligonucleotide facilitators enable a hammerhead ribozyme to cleave long RNA with multiple-turnover activity
45. Optimizing the cell efficacy of synthetic ribozymes. Site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb
46. Target-specific arrest of mRNA translation by antisense 2′-O-alkyl-oligoribonucleotides
47. The induction of apoptosis in HeLa cells by the loss of LBP-p40
48. Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA
49. Delivery of a hammerhead ribozyme specifically down-regulates the production of fibrillin-1 by cultured dermal fibroblasts
50. Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of Japan (HVJ)-cationic liposomes. Application for ribozymes that target human t-cell leukaemia virus type I tax/rex mRNA
51. Cleavage of specific sites of RNA by designed ribozymes
52. Designing of chimeric DNA/RNA hammerhead ribozymes to be targeted against AML1/MTG8 mRNA
53. Full-length sequence, localization, and chromosomal mapping of ameloblastin. A novel tooth-specific gene
54. Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of tetrahymena
55. Characterization of several types of dimer minizymes: Simultaneous cleavage at two sites in HIV-1 tat mRNA by dimer minizymes
56. Antisense oligonucleotides made of 2′-O-alkyl RNA: Their properties and applications in RNA biochemistry
57. Defining the inside and outside of a catalytic RNA molecule
58. High cleavage activity and stability of hammerhead ribozymes with a uniform 2′-amino pyrimidine modification
59. Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library
60. Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with stem II deletions
61. 17
62. A synthetic chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo
63. In vivo knock out of a tissue-specific gene by synthetic ribozymes
64. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes
65. Cationic liposome-mediated RNA transfection
66. Minimal sequence requirements for ribozyme activity
67. Structure and function of the hammerhead ribozyme: An unfinished story
68. A mutation-independent therapeutic strategem for osteogenesis imperfecta
69. Nuclease resistant ribozymes with high catalytic activity
70. Fluorescence resonance energy transfer analysis of ribozyme kinetics reveals the mode of action of a facilitator oligonucleotide
71. Mixed deoxyribo- and ribo-oligonucleotides with catalytic activity
72. Extended target-site specificity for a hammerhead ribozyme
73. Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes
74. Three-dimensional structure of a hammerhead ribozyme
75. Ribozymes: A distinct class of metalloenzymes
76. Sequence requirements of the hammerhead RNA self-cleavage reaction
77. Dopamine D(2) receptor ribozyme inhibits quinpirole-induced stereotypy in rats
78. Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo. Oligoribonucleotides as therapeutic agents
79. Ribozymes structure and mechanism in RNA catalysis
80. Cleavage of the highly conserved hairpin-loop region of HIV-1 by synthetic ribozymes
81. Generality of the NUX rule: Kinetic analysis of the results of systematic mutations in the trinucleotide at the cleavage site of hammerhead ribozymes
82. Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by peritoneal cells in vitro and in vivo
83. Enhancement of hammerhead ribozyme catalysis by glyceraldehyde-3-phosphate dehydrogenase
84. Substitution of the 2′-hydroxyl group at position 2.1 by an amino group interferes with Mg(2+) binding and efficient cleavage by hammerhead ribozyme
85. In vivo decay kinetic parameters of hammerhead ribozymes
86. Self-cleavage of RNA in the replication of viroids and virusoids
87. Ribozyme-mediated down-regulation of Erb-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo
88. Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection
89. Activity of hammerhead ribozymes containing non-nucleotidic linkers
90. Protein enhancement of hammerhead ribozyme catalysis
91. Hammerhead ribozymes: Importance of stem-loop II for activity
92. A three-dimensional model for the hammerhead ribozyme based on fluorescence measurements
93. A small catalytic oligoribonucleotide
94. Hammerhead ribozyme engineering
95. In vitro selection of a purine nucleotide-specific hammerheadlike ribozyme
96. Synthetic 2′-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity
97. Ribozymes which cleave arena virus RNAs: Identification of susceptible target sites and inhibition by target site secondary structure
98. Minimum ribonucleotides requirement for catalysis by the RNA hammerhead domain
99. In vitro optimization of truncated stem-loop II variants of the hammerhead ribozyme for cleavage in low concentrations of magnesium under non-turnover conditions
100. Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes